FDA approves first generic Abilify

FDA approved the first generic versions of Abilify (aripiprazole), an antipsychotic drug approved to treat schizophrenia and bipolar disorder. » Read more

Idiopathic Pulmonary Fibrosis (IPF)
IPF is the progressive formation of thick or scarred tissue in the lungs, resulting in loss of oxygen. While there is currently no known cause, continued research seeks to find an answer, alongside improved diagnosis and treatment options. Learn More

Chronically ill patients fearful of unreported drug switching by insurers, PBMs

Insurers and pharmacists should not switch effective therapies without patient and physician notification, according to a national survey of stabilized autoimmune patients that explored their perspectives on switching prescribed biological medicines.
» Survey details

Continuing Education

MTM essentials for asthma: Part 1

This month Drug Topics and the University of Connecticut School of Pharmacy offer a new CPE series: MTM for the patient with respiratory disease. Pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities (released April – December 2015). This month the series kicks off with MTM essentials for asthma management, covering the pathophysiology of asthma, clinical presentations of asthma, assessment methods, and nonpharmacologic management options.

To read and print the article with TEST questions, click here

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT29-YKX36.

Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

Drugs in Perspective: Opdivo (nivolumab)

Approximately 76,100 new cases of melanoma and 9,710 deaths from melanoma were anticipated in the United States in 2014. Explore melanoma pipeline agents and take a closer look at recently approved breakthrough therapy, Opdivo (nivolumab).
» Nivolumab dose modifications

• Children's use of antipsychotics may increase risk of diabetes

• FDA: Diabetes drugs don’t need death warning

RESOURCES

Latest Clinical News